IP Library › Granted Patent US 12,453,767
Granted Patent B2
US 12,453,767 · App. 17/889,737 · Granted Oct 28, 2025

Development of mosaic vaccines against foot and mouth disease virus serotype O

Inventors: Aida E. Rieder (Westbrook, CT); Katherine M. Pflaum (Middletown, CT); Fayna C. Diaz San Segundo (Blue Point, NY); William M. Fischer (Los Alamos, NM); Tatjana Sitt (Essex, CT)
Assignees: The United States of America, as represented by the Secretary of Agriculture; Kansas State University Research Foundation; Triad National Security, LLC
A61K39/135A61P31/14A61K2039/552
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,453,767
App. No.
17/889,737
Granted
Oct 28, 2025
Kind
B2
Abstract

Synthetic foot-and-mouth disease virus (FMDV) mosaic polypeptides, and nucleic acid molecules encoding the mosaic polypeptides, are described. When included as part of an FMDV genome, the mosaic polypeptides permit virus replication and assembly into FMDV particles. The mosaic polypeptide and nucleic acid compositions can be used to elicit immune responses that provide protection against a broad range of serotype O FMDV strains.

Claims (12)

1. A synthetic polypeptide comprising the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 10.

2. The synthetic polypeptide of claim 1 , further comprising a pharmaceutically acceptable carrier.

3. The synthetic polypeptide of claim 1 , comprising a first and a second synthetic polypeptide wherein the first synthetic polypeptide comprises the amino acid sequence of SEQ ID NO: 2, and the second synthetic polypeptide comprises the amino acid sequence of SEQ ID NO: 10, and optionally a pharmaceutically acceptable carrier.

4. The synthetic polypeptide of claim 3 , further comprising an adjuvant.

5. An isolated nucleic acid molecule encoding the synthetic polypeptide of claim 1 .

6. A vector comprising the isolated nucleic acid molecule of claim 5 .

7. A recombinant foot-and-mouth disease virus (FMDV) comprising a synthetic polypeptide having the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 10.

8. The recombinant FMDV of claim 7 , comprising a first and a second recombinant FMDV, wherein the first recombinant FMDV comprises a synthetic polypeptide having the amino acid sequence of SEQ ID NO: 2, and the second recombinant FMDV comprises a synthetic polypeptide having the amino acid sequence of SEQ ID NO: 10, and further optionally comprising a pharmaceutically acceptable carrier.

9. A method of eliciting an immune response against serotype O foot-and-mouth disease virus (FMDV) in a subject, comprising administering to the subject a composition comprising a synthetic polypeptide having the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 10, thereby eliciting an immune response to serotype O FMDV.

10. The method of claim 9 , wherein the composition further comprises a pharmaceutically acceptable carrier, an adjuvant, or both a pharmaceutically acceptable carrier and an adjuvant.

11. The method of claim 9 , comprising administering to the subject a first composition comprising a synthetic polypeptide having the amino acid sequence of SEQ ID NO: 2 and a second composition comprising a second synthetic polypeptide at least 98% identical to the amino acid sequence of SEQ ID NO: 10.

12. The method of claim 9 , wherein the subject is a cow or a pig.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2023
From: RIEDER, AIDA E; PFLAUM, KATHERINE M; DIAZ SAN SEGUNDO, FAYNA C
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE
Reel/Frame 062923/0829 →
Continuity (2)
Provisional Application 63234458 · Aug 18, 2021
Related Publication 20230149528A1 · May 18, 2023
References Cited (16)
US 7323546B2 · Liang et al. · 2008 [cited by applicant]
US 8409588B2 · Czub et al. · 2013 [cited by applicant]
US 10010605B2 · Audonnet et al. · 2018 [cited by applicant]
US 10308927B2 · Puckette et al. · 2019 [cited by applicant]
US 20170216422A1 · Widener et al. · 2017 [cited by applicant]
US 20230149528A1 · Rieder · 2023 [cited by examiner]
WO WO2014077825A1 · 2014 [cited by examiner]
SEQ ID No. 2 alignment with UniProt_202406 access No. Q8JW41_FMDVO Oct. 2002. [cited by examiner]
SEQ ID No. 4 alignment with UniProt_202406 access No. POLG_FMDVP Jul. 2004. [cited by examiner]
SEQ ID No. 6 alignment with PIR_80 db access No. GNNYF submitted 1981. [cited by examiner]
SEQ ID No. 6 alignment with UniProt_202406 access No. L0AQ77_FMDVO Mar. 2013. [cited by examiner]
SEQ ID No. 8 alignment with UniProt_202406 access No. A0A0H3VYK9_FMDVO Oct. 2015. [cited by examiner]
SEQ 10 alignment with UniProt_202406 access No. A0A119J6C3_FMDVO Feb. 2017. [cited by examiner]
SEQ 2 alignment with Geneseq db access BBG42659 in WO2014077825 May 2014. [cited by examiner]
SEQ 10 alignment with Geneseq db access BGQ54277 in CN110156896 Oct. 2019. [cited by examiner]
International Search Report dated Dec. 15, 2022. [cited by applicant]